Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endometrin is a brand-name vaginal insert containing micronized progesterone, a naturally occurring steroid hormone essential for establishing and maintaining pregnancy. It is used as part of Assisted Reproductive Technology (ART) programs to support embryo implantation and early pregnancy by supplementing corpus luteal function in infertile women. Progesterone transforms the endometrium from a proliferative to a secretory state, increasing its receptivity for embryo implantation and supporting early gestation. Endometrin is administered intravaginally at 100 mg two or three times daily, typically starting the day after oocyte retrieval and continuing for up to 10 weeks[1][2][3][6]. The product is only available as a brand-name medication; no generic equivalent exists[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on endometrin.